Anticoagulant therapy and home blood pressure-associated risk for stroke/bleeding events in elderly patients with non-valvular atrial fibrillation: the sub-cohort study of ANAFIE registry

[1]  W. Shimizu,et al.  Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry , 2021, European heart journal. Quality of care & clinical outcomes.

[2]  K. Kario,et al.  High prevalence of masked uncontrolled morning hypertension in elderly non‐valvular atrial fibrillation patients: Home blood pressure substudy of the ANAFIE Registry , 2020, Journal of clinical hypertension.

[3]  G. Lippi,et al.  Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge , 2020, International journal of stroke : official journal of the International Stroke Society.

[4]  Yoshihiko Kanno,et al.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) , 2019, Hypertension Research.

[5]  Y. Chun,et al.  Relationship of Hypertension and Systolic Blood Pressure With the Risk of Stroke or Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry , 2017, American journal of hypertension.

[6]  G. Breithardt,et al.  Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. , 2016, American heart journal.

[7]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[8]  S. Yusuf,et al.  Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). , 2015, The American journal of cardiology.